Daniel R Kuritzkes Selected Research

vicriviroc

8/2010	Three-year safety and efficacy of vicriviroc, a CCR5 antagonist, in HIV-1-infected treatment-experienced patients.
12/2009	Response to vicriviroc in treatment-experienced subjects, as determined by an enhanced-sensitivity coreceptor tropism assay: reanalysis of AIDS clinical trials group A5211.
3/2009	Lymphoma diagnosis and plasma Epstein-Barr virus load during vicriviroc therapy: results of the AIDS Clinical Trials Group A5211.
7/2007	Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211.
2/2007	HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Daniel R Kuritzkes Research Topics

Disease

30	Acquired Immunodeficiency Syndrome (AIDS) 10/2022 - 09/2002
22	Infections 01/2021 - 09/2002
17	Viremia 10/2022 - 04/2005
12	HIV Infections (HIV Infection) 01/2021 - 05/2003
5	COVID-19 12/2022 - 10/2020
5	Inflammation (Inflammations) 10/2020 - 08/2013
3	Lymphoma (Lymphomas) 01/2018 - 03/2009
3	Neoplasms (Cancer) 01/2018 - 07/2007
3	Tuberculosis (Tuberculoses) 01/2013 - 02/2009
3	Insulin Resistance 05/2011 - 05/2003
2	Latent Infection 06/2017 - 01/2016
2	Cardiovascular Diseases (Cardiovascular Disease) 01/2017 - 05/2011
2	Disease Progression 05/2011 - 04/2011
2	Lactic Acidosis 12/2007 - 11/2007
2	Pancreatitis 12/2007 - 11/2007
1	Neural Tube Defects (Exencephaly) 01/2020
1	Weight Gain 01/2020
1	Castleman Disease (Castleman's Disease) 01/2018
1	Hematologic Neoplasms (Hematological Malignancy) 01/2017
1	Kaposi Sarcoma (Kaposi's Sarcoma) 06/2015
1	Metabolic Syndrome (Dysmetabolic Syndrome X) 01/2015
1	Hyperbilirubinemia 10/2014
1	Breakthrough Infections 01/2011
1	Virus Diseases (Viral Diseases) 12/2010
1	Non-Hodgkin Lymphoma (Lymphosarcoma) 03/2009

Drug/Important Bio-Agent (IBA)

15	RNA (Ribonucleic Acid)IBA 01/2021 - 09/2002
13	DNA (Deoxyribonucleic Acid)IBA 10/2022 - 09/2003
9	efavirenz (Sustiva)FDA Link 03/2010 - 04/2004
8	Pharmaceutical PreparationsIBA 12/2022 - 05/2003
7	Reverse Transcriptase InhibitorsIBA 01/2016 - 04/2004
7	NucleosidesIBA 01/2016 - 04/2004
5	LipidsIBA 01/2017 - 04/2007
5	Ritonavir (Norvir)FDA Link 01/2015 - 01/2012
5	vicrivirocIBA 08/2010 - 02/2007
4	Raltegravir Potassium FDA Link 01/2017 - 03/2011
4	VaccinesIBA 11/2014 - 02/2010
4	abacavir (Ziagen)FDA Link 05/2011 - 04/2004
3	Antiviral Agents (Antivirals)IBA 12/2022 - 07/2005
3	Protease Inhibitors (Protease Inhibitor)IBA 11/2020 - 04/2004
3	Biomarkers (Surrogate Marker)IBA 01/2019 - 04/2005
3	Integrase InhibitorsIBA 01/2015 - 03/2011
3	Lamivudine (Epivir)FDA Link 04/2007 - 04/2004
2	Oxygen (Dioxygen)IBA 12/2022 - 01/2022
2	C-Reactive ProteinIBA 10/2020 - 05/2011
2	oxidized low density lipoproteinIBA 01/2017 - 04/2007
2	HDL CholesterolIBA 01/2017 - 04/2007
2	RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA 06/2015 - 09/2012
2	Darunavir (Prezista)FDA Link 10/2014 - 08/2013
2	Lopinavir FDA Link 01/2013 - 01/2012
2	Rifampin (Rifampicin)FDA LinkGeneric 01/2013 - 01/2012
2	Enfuvirtide (Fuzeon)FDA Link 03/2011 - 05/2003
2	Proteins (Proteins, Gene)FDA Link 12/2010 - 09/2010
2	AntigensIBA 03/2009 - 09/2002
2	Zidovudine (Retrovir)FDA LinkGeneric 04/2007 - 04/2004
2	Glucose (Dextrose)FDA LinkGeneric 04/2007 - 05/2003
2	Triglycerides (Triacylglycerol)IBA 04/2007 - 01/2003
1	nirmatrelvir and ritonavir drug combinationIBA 12/2022
1	Histones (Histone)IBA 10/2022
1	Tamoxifen FDA LinkGeneric 10/2022
1	Vorinostat FDA Link 10/2022
1	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2022
1	Complement System Proteins (Complement)IBA 01/2022
1	remdesivirIBA 01/2022
1	tenofovir diphosphateIBA 12/2021
1	bamlanivimabIBA 01/2021
1	Interleukin-6 (Interleukin 6)IBA 10/2020
1	dolutegravirIBA 01/2020
1	Brentuximab VedotinIBA 01/2018
1	Rituximab (Mabthera)FDA Link 01/2018
1	B 31IBA 11/2017
1	CXCR4 Receptors (CXCR4 Receptor)IBA 06/2016
1	CC ChemokinesIBA 06/2016
1	Artificial SalivaIBA 06/2015
1	Immunologic Factors (Immunomodulators)IBA 05/2015
1	HLA-DR Antigens (HLA-DR)IBA 01/2015
1	InterferonsIBA 11/2014
1	Atazanavir Sulfate (Reyataz)FDA Link 10/2014
1	AntibodiesIBA 08/2013
1	NucleotidesIBA 09/2012
1	Tenofovir (Viread)FDA Link 08/2012
1	IntegrasesIBA 03/2011
1	Maraviroc FDA Link 01/2011
1	GelsIBA 01/2011
1	Peptides (Polypeptides)IBA 12/2010
1	Amino Acids FDA Link 12/2010
1	HLA Antigens (Human Leukocyte Antigens)IBA 12/2010
1	Nevirapine (Viramune)FDA Link 03/2010
1	Anti-Infective Agents (Microbicides)IBA 02/2010

Therapy/Procedure

17	Therapeutics 10/2022 - 09/2002
12	Art Therapy 12/2021 - 08/2012
6	Highly Active Antiretroviral Therapy (HAART) 01/2017 - 09/2002
3	Drug Therapy (Chemotherapy) 01/2018 - 01/2009
2	Stem Cell Transplantation 01/2018 - 01/2017
2	Salvage Therapy 07/2005 - 04/2003
1	Extracorporeal Membrane Oxygenation 01/2022
1	Noninvasive Ventilation 01/2022
1	Artificial Respiration (Mechanical Ventilation) 01/2022
1	Optical Devices 01/2021
1	Hematopoietic Stem Cell Transplantation 01/2018
1	Immunotherapy 02/2010